161 related articles for article (PubMed ID: 23118991)
21. No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Yuan P; Liu L; Wu C; Zhong R; Yu D; Wu J; Xu Y; Nie S; Miao X; Sun Y; Xu B; Lin D
Cancer Biol Ther; 2010 Nov; 10(9):854-9. PubMed ID: 20814250
[TBL] [Abstract][Full Text] [Related]
22. An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy.
Zhang R; Jia M; Xu Y; Qian D; Wang M; Zhu M; Sun M; Chang J; Wei Q
Int J Cancer; 2018 Mar; 142(6):1218-1229. PubMed ID: 29134637
[TBL] [Abstract][Full Text] [Related]
23. Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer.
Dong J; Wang X; Yu Y; Yan X; Cui JW
Chin Med J (Engl); 2018 Aug; 131(16):1904-1908. PubMed ID: 30082520
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
[TBL] [Abstract][Full Text] [Related]
25. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
[TBL] [Abstract][Full Text] [Related]
26. Role of ERCC5 polymorphisms in non‑small cell lung cancer risk and responsiveness/toxicity to cisplatin‑based chemotherapy in the Chinese population.
Li M; Chen R; Ji B; Fan C; Wang G; Yue C; Jin G
Oncol Rep; 2021 Mar; 45(3):1295-1305. PubMed ID: 33469680
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.
Yu D; Shi J; Sun T; Du X; Liu L; Zhang X; Lu C; Tang X; Li M; Xiao L; Zhang Z; Yuan Q; Yang M
Tumour Biol; 2012 Jun; 33(3):877-84. PubMed ID: 22249976
[TBL] [Abstract][Full Text] [Related]
28. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis.
Yu SN; Liu GF; Li XF; Fu BH; Dong LX; Zhang SH
J Cell Biochem; 2017 Dec; 118(12):4782-4791. PubMed ID: 28520216
[TBL] [Abstract][Full Text] [Related]
30. Association between DNA mismatch repair gene polymorphisms and platinum-based chemotherapy toxicity in non-small cell lung cancer patients.
Liu JY; Qian CY; Gao YF; Chen J; Zhou HH; Yin JY
Chin J Cancer; 2017 Jan; 36(1):12. PubMed ID: 28093084
[TBL] [Abstract][Full Text] [Related]
31. Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer.
Provencio M; Camps C; Cobo M; De las Peñas R; Massuti B; Blanco R; Alberola V; Jimenez U; Delgado JR; Cardenal F; Tarón M; Ramírez JL; Sanchez A; Rosell R
Cancer Chemother Pharmacol; 2012 Dec; 70(6):883-90. PubMed ID: 23053267
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.
Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Delgado JR; Faus-Dáder MJ; Calleja-Hernández MŸ
Pharmacol Res; 2016 Sep; 111():877-884. PubMed ID: 27498158
[TBL] [Abstract][Full Text] [Related]
33. DNA repair gene polymorphisms in non-small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
Rulli E; Marabese M; Piva S; Bonomi L; Caiola E; Ganzinelli M
Tumori; 2016 Aug; 102(4):367-75. PubMed ID: 27396427
[TBL] [Abstract][Full Text] [Related]
34. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
Isla D; Sarries C; Rosell R; Alonso G; Domine M; Taron M; Lopez-Vivanco G; Camps C; Botia M; Nuñez L; Sanchez-Ronco M; Sanchez JJ; Lopez-Brea M; Barneto I; Paredes A; Medina B; Artal A; Lianes P
Ann Oncol; 2004 Aug; 15(8):1194-203. PubMed ID: 15277258
[TBL] [Abstract][Full Text] [Related]
35. Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.
Qian J; Gu S; Wu Q; Zhao X; Wu W; Gao Z; Zhang W; Tan X; Wang H; Wang J; Fan W; Chen H; Han B; Lu D; Wei Q; Jin L
Chest; 2012 Sep; 142(3):680-689. PubMed ID: 22441531
[TBL] [Abstract][Full Text] [Related]
36. Association between eIF3α polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients.
Xu X; Han L; Duan L; Zhao Y; Yang H; Zhou B; Ma R; Yuan R; Zhou H; Liu Z
Br J Clin Pharmacol; 2013 Feb; 75(2):516-23. PubMed ID: 22804784
[TBL] [Abstract][Full Text] [Related]
37. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.
Yao CY; Huang XE; Li C; Shen HB; Shi MQ; Feng JF; Pan LX; Tang JH
Asian Pac J Cancer Prev; 2009; 10(5):859-64. PubMed ID: 20104979
[TBL] [Abstract][Full Text] [Related]
38. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.
Su D; Ma S; Liu P; Jiang Z; Lv W; Zhang Y; Deng Q; Smith S; Yu H
Lung Cancer; 2007 May; 56(2):281-8. PubMed ID: 17222938
[TBL] [Abstract][Full Text] [Related]
39. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
[TBL] [Abstract][Full Text] [Related]
40. Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.
Qian J; Qu HQ; Yang L; Yin M; Wang Q; Gu S; Wu Q; Zhao X; Wu W; Wu J; Tan X; Chen W; Wang H; Wang J; Fan W; Chen H; Han B; Lu D; Wei Q; Jin L
Oncologist; 2012; 17(12):1551-61. PubMed ID: 22843554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]